Mayne And Mithra Receive Australian Nextstellis Approval

Launch Expected In Mid-2022 After TGA Endorses Estetrol/Drospirenone Contraceptive

 
• By Dave Wallace

Mayne Pharma and Mithra have revealed launch plans in Australia for their Nextstellis oral contraceptive that combines the novel estrogen estetrol with drospirenone, following approval by the TGA.

Australian_Dollars
Mayne sees potential in the Australian contraceptive market • Source: Shutterstock

More from Value Added Medicines

More from Products